Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propensity matched one-year results from interventional cardiology network registry

2018 ◽  
Vol 93 (7) ◽  
pp. E362-E368 ◽  
Author(s):  
Pawel Gasior ◽  
Marek Gierlotka ◽  
Krzysztof Szczurek-Katanski ◽  
Marcin Osuch ◽  
Roman Gnot ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Interventional Cardiology ◽  
Daily Clinical Practice ◽  
Durable Polymer ◽  
Bioresorbable Polymer ◽  
Sirolimus Eluting Stent ◽  
One Year

scholarly journals One Year with the COVID-19 Pandemic - Lessons Learnt? Intersectoral Collaboration Measures Established during the Crisis Could Benefit Capacity and Patient Flow Management in Daily Clinical Practice

2021 ◽  
Vol 8 (3) ◽  
Author(s):  
Hiller M ◽  
◽  
Bracht H ◽  
Schroeder S ◽  
◽  
...  
Keyword(s):  
Clinical Practice ◽  
Positive Impact ◽  
Patient Flow ◽  
Resource Planning ◽  
Daily Clinical Practice ◽  
Intersectoral Collaboration ◽  
Patient Pathways ◽  
Patient Flow Management ◽  
One Year ◽  
Communication Culture

The COVID-19 pandemic has changed the way hospitals work. Some of the urgently established measures have proven to be so useful that they should be adopted in standard care. Recent research has assessed patient management, human resource planning and communication measures in terms of their impact and practicality for continuation in daily clinical practice. Strategies that were detached from the boundaries of departments and responsibilities in the COVID-19 pandemic and that have proven themselves under extreme conditions show a beneficial influence on patient flow and resource management as well as on the communication culture. The continuation of closer interdisciplinary and cross-sectoral cooperation in a “new clinical routine” could have a positive impact on personnel concepts, communication strategies, acute care capacities and the management of patient pathways.

scholarly journals Early and chronic phased local coagulative responses following bioresorbable-polymer drug-eluting stent implantation

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
K Yamaguchi ◽  
T Wakatsuki ◽  
Y Okushi ◽  
K Suto ◽  
K Matsumoto ◽  
...  
Keyword(s):  
Dual Antiplatelet Therapy ◽  
Chronic Phase ◽  
Time Dependent ◽  
Drug Eluting Stent ◽  
Sinus Of Valsalva ◽  
Funding Sources ◽  
Durable Polymer ◽  
Drug Eluting ◽  
Bioresorbable Polymer ◽  
Sirolimus Eluting Stent

Abstract Background Neointimal maturation after bioresorbable-polymer (BP) drug-eluting stent (DES) implantation will not be complete in the absorption phase of the polymer. We have previously reported local persistent hypercoagulation after sirolimus-eluting stent (SES) implantation by measuring local plasma prothrombin fragment 1+2 (F1+2) levels. The aim of this study is to examine time-dependent local coagulative response after BP-DES implantation. Methods Sixty-four patients who were treated about ten months earlier with coronary angioplasty, with no evidence of restenosis, were studied [durable-polymer (DP)-DES {SES; Cypher®: 26pts and everolimus-eluting stent (EES); Xience®: 16pts} and BP-DES (BP-EES; Synergy®: 10pts and BP-SES; Ultimaster®: 12pts)]. We measured plasma levels of F1+2 sampled in coronary sinus (CS) and sinus of Valsalva (V) at the early (2±1 months) and chronic (10±2 months) phases. The transcardiac gradient (Δ) was defined as CS level minus V level. Results No significant differences were observed in the percent diameter stenosis between the DP- and BP- DES groups (11.5±15.5 vs 14.1±11.9%). The ΔF1+2 was significantly lower in the BP-DES group than in the DP-DES group at the chronic phase (7.5±16.1 vs 16.4±17.1pmol/l, p<0.05). In the BP-DES group, the ΔF1+2 did not differ significantly between the early and chronic phases (7.0±14.1 vs 7.5±16.1pmol/l, NS). Conclusion Lower local coagulative response was observed at the chronic phase after BP-DES implantation compared to DP-DES implantation, and local hypercoagulation after BP-DES implantation was not observed at the early phase compared to the chronic phase. These findings might lead to the possibility of shorter dual antiplatelet therapy after BP-DES implantation. FUNDunding Acknowledgement Type of funding sources: None.

scholarly journals Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer‐Generation Drug‐Eluting Stents

2021 ◽  
Author(s):  
Rayyan Hemetsberger ◽  
Mohammad Abdelghani ◽  
Ralph Toelg ◽  
Nader Mankerious ◽  
Abdelhakim Allali ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Intervention ◽  
Target Lesion ◽  
Drug Eluting Stents ◽  
Target Vessel ◽  
Durable Polymer ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Bioresorbable Polymer ◽  
Sirolimus Eluting Stent

Background Percutaneous coronary intervention of calcified lesions was associated with worse outcomes in the era of bare‐metal and first‐generation drug‐eluting stents. Data on percutaneous coronary intervention of calcified lesions with newer‐generation drug‐eluting stents are scarce. Therefore, we investigated the impact of lesion calcification on clinical outcomes in patients undergoing percutaneous coronary intervention with a bioresorbable‐polymer sirolimus‐eluting stent or a durable‐polymer everolimus‐eluting stent. Methods and Results Patients (n=2361) from BIOFLOW II, IV, and V trials were categorized into moderate/severe versus none/mild lesion calcification by a core laboratory. End points were target‐lesion failure (TLF) (cardiac death, target‐vessel myocardial infarction, or target‐lesion revascularization) and probable/definite stent thrombosis at 2 years. The agreement in calcification assessment between the operator and the core laboratory was weak (weighted κ, 0.23). Patients with moderate/severe calcification (n=303; 16%) had higher TLF (13.5% versus 8.4%; P =0.003) and stent thrombosis rates (2.1% versus 0.2%; P <0.0001), whereas target‐lesion revascularization was not different between the groups (5.0% versus 3.9%; P =0.302). After adjustment, calcification did not emerge as an independent predictor of TLF (adjusted hazard ratio [aHR], 1.37; 95% CI, 0.89–2.08; P =0.148) but did for target‐vessel myocardial infarction (aHR, 1.66; 95% CI, 1.03–2.68; P =0.037). TLF rates were similar between bioresorbable‐polymer sirolimus‐eluting stent and durable‐polymer everolimus‐eluting stent (12.6% versus 15.4%, P =0.482) in moderate/severe calcification. In none/mild calcification, the bioresorbable‐polymer sirolimus‐eluting stent showed lower TLF (7.5% versus 10.3%, P =0.045). Conclusions With newer‐generation drug‐eluting stents, moderate/severe lesion calcification was not associated with more TLF after adjustment for the higher risk of patients with coronary calcification, whereas the rate of target‐vessel myocardial infarction was higher. The bioresorbable‐polymer sirolimus‐eluting stent and durable‐polymer everolimus‐eluting stent were equally effective and safe in calcified lesions. Registration URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01356888, NCT01939249, NCT02389946.

Sign in / Sign up

Export Citation Format

Share Document